Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harrow Health Inc anticipates breakout year in 2023 post-successful Q4

Harrow Health Inc's Q4 2022 call showcased a strong performance, emphasizing strategic acquisitions and growth prospects for 2023. While challenges in expense management and pricing strategies exist, the company's leadership is focused on maximizing opportunities and delivering value to stakeholders.

Harrow Health Inc excels in Q1, poised for ophthalmic market leadership

Harrow Health Inc's Q1 2023 earnings call highlighted robust financial performance, a strategic roadmap for market leadership in ophthalmic pharmaceuticals, and positive early indicators for product success. While facing challenges in product formulations and margins, the company's focus on customer feedback and commercialization strategies presents significant growth opportunities.

Harrow Health Inc reports revenue growth driven by key products

Harrow Health Inc's Q2 2023 performance reflects positive revenue growth and a strong market position driven by VEVYE and IHEEZO.
While facing challenges with leverage ratios and net equity, the company's flexible approach and growth outlook offer opportunities for improvement.
Strengthened by recent acquisitions and stakeholder support, Harrow Health is poised for continued growth and market competitiveness.
Investors should monitor the company's financial leverage, revenue drivers, and market strategies for insights into its future performance.

Harrow Health Inc achieves record revenues, eyes market expansion

Harrow Health Inc reported strong financial performance with record revenues and growth in key metrics.
While facing challenges in certain product revenues and the compounding business, the company is optimistic about new product opportunities.
Management's confidence in the company's prospects and goals reflects a positive outlook for stakeholders.

Harrow Health Inc reports stellar Q4 results and eyes market dominance

Harrow Health Inc's Q4 2023 performance reflects robust financial growth, strategic successes, and a resilient market position, setting the stage for continued expansion.
While facing challenges such as a cyber attack impact and operational hurdles, the company's strengths in strategic focus, pricing strategy, and market opportunities position it well for future success.
With a clear vision for growth, a commitment to value creation, and a focus on market dominance in key segments, Harrow Health Inc is poised for sustained growth and profitability in the coming year.

Harrow Health Inc (HROW) achieves record Q3 revenue growth

Harrow Health Inc (HROW) reported strong Q3 performance with record revenue, driven by VEVYE and IHEEZO. The company is focused on sustainable growth, long-term vision, and value creation for stakeholders. Challenges include temporary inventory shortages and limited direct-to-consumer advertising plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery

ImprimisRx® Announces Supply Agreement with iOR Partners

ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed during ophthalmic surgery ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed during ophthalmic surgery

ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA)

Investors need to pay close attention to Harrow Health (HROW) stock based on the movements in the options market lately.

Implied Volatility Surging for Harrow Health (HROW) Stock Options

SAN DIEGO, Dec.  10, 2019  (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients.  

ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License

Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2019 Results - Earnings Call Transcript

Harrow (HROW) delivered earnings and revenue surprises of -2.27% and -4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Harrow Health (HROW) Reports Q3 Loss, Misses Revenue Estimates

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to Decline

BOSTON, Oct.  23, 2019  (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors. Dr. Adair is a Co-Founder and Managing Director of Solas BioVentures, a venture capital fund that invests exclusively in the Life Sciences industry. Dr. Adair has extensive experience serving as a director on the boards of several pharmaceutical and medical device companies, including companies specializing in women’s health, in addition to 21 years as an OB/GYN Department Professor and Vice Chairman at the University of Tennessee College of Medicine in Chattanooga. Solas BioVentures intends to participate in the Mayfield Pharmaceuticals Series A financing.

Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors

BOSTON, Oct.  08, 2019  (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa Bradford-Klug, will discuss Mayfield’s advancements in developing new anti-infective medications such as its MAY-66 drug candidate for recurrent bacterial vaginosis, as well as Mayfield’s programs for dyspareunia and interstitial cystitis, at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10th, 2019 at 3:45 p.m. ET at the SVB Leerink offices in New York, NY.  Bradford-Klug will be available to meet with attendees who may contact their SVB Leerink representative to arrange for a meeting. 

Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019

SAN DIEGO, Oct.  08, 2019  (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation at the upcoming 2019 American Academy of Ophthalmology (AAO) Annual Meeting to be held at the Moscone Center in San Francisco, CA, October 12-15. The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons, encompassing a community of 32,000 medical doctors. More than 90 percent of practicing ophthalmologists are AAO members. The annual meeting includes a global community of innovators in the art and science of ophthalmology in addition to game-changing research, techniques, and technologies.

ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting

News for Harrow Health Inc Stock (HROW)